| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 8,200 |
| Other | 0 |
| Net income (loss) | 44,692 |
| Prepaid expenses and other current assets | -5,915 |
| Other non-current liabilities | -366 |
| Other non-current assets | -244 |
| Lease liabilities, net | -32,654 |
| Deferred revenue | -144,122 |
| Accrued liabilities | -23,221 |
| Accounts payable | 1,445 |
| Depreciation | 2,713 |
| Net accretion of discounts on marketable securities | 1,254 |
| Termination of prepaid contracts and other costs | 915 |
| Purchase of net (premiums) discounts on marketable securities | 307 |
| Non-cash lease expense | 1,603 |
| Impairment and disposal of long-lived assets | 52,889 |
| Net cash used in operating activities | -83,308 |
| Proceeds from sales of property, plant and equipment | 2,372 |
| Proceeds from maturities and sales of marketable securities | 101,122 |
| Purchase of property, plant and equipment | 32 |
| Purchases of marketable securities | 16,184 |
| Net cash provided by investing activities | 87,278 |
| Proceeds from purchases under the employee stock purchase plan | 4 |
| Proceeds from exercise of stock options | 13 |
| Payment of employee taxes and exercise costs for shares withheld | 0 |
| Payment of deferred offering costs | 0 |
| Net cash provided by financing activities | 17 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 3,987 |
IGM Biosciences, Inc. (IGMS)
IGM Biosciences, Inc. (IGMS)